• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    DexCom Stock Has The Bull Case Changed After The Canada Launch And Guidance Raise

    Simply Wall St·11/04/2026 21:32:45
    Listen to the news
    • DexCom reported third quarter 2026 sales of US$1.34b with stable basic EPS from continuing operations, raised full year revenue guidance, and announced a US$1b share repurchase program running through the end of 2027.
    • The upcoming Canadian rollout of the Dexcom G7 15 Day CGM, supported by broad public and private reimbursement, adds a fresh international growth lever alongside these financial updates.
    • This article examines how DexCom's investment narrative is influenced by the G7 15 Day Canadian launch and the raised full year guidance.

    See how DexCom’s latest earnings, guidance lift and buyback plan compare with other potential breakouts in healthcare by reviewing the hand picked 34 healthcare AI stocks.

    DexCom Investment Narrative Recap

    To own DexCom, you need to believe continuous glucose monitoring keeps gaining traction across type 1, type 2 non insulin and prediabetes, and that the firm can keep improving profitability as it scales. The raised 2026 revenue outlook to US$5.20b to US$5.25b ties that story more tightly to execution on new markets and products rather than financial engineering.

    The biggest near term swing factor still looks like access and adoption in broader type 2 and international segments, where coverage decisions and on the ground execution decide how quickly the user base grows. Key risks remain Medicare pricing pressure, more aggressive competition and potential margin drag from the Ireland plant ramp.

    The most relevant update is DexCom’s move to lift full year 2026 revenue guidance to US$5.20b to US$5.25b, framed by Q3 sales of US$1.34b and nine month revenue of US$3.84b. That guidance range sets a clear operational bar around volume growth, payer coverage and manufacturing efficiency over the next few quarters.

    For you as an investor, the guidance increase links directly to the main catalysts. It assumes DexCom executes on G7 15 Day rollouts, including Canada, continues expanding into type 2 non insulin populations and manages reimbursement and pricing headwinds without eroding its margin ambitions, all while preparing for the Ireland facility impact from 2027.

    DexCom's narrative projects US$6.8b revenue and US$1.5b earnings by 2029. This assumes revenue growth of 11.1% per year and an earnings increase of roughly US$500m from the current US$999.7m base.

    Uncover how DexCom's fair value indicates a 16% potential upside to its current price before the market closes that discount.

    NasdaqGS:DXCM 1-Year Stock Price Chart
    NasdaqGS:DXCM 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on DexCom focuses on slower CGM adoption among covered type 2 patients. The most pessimistic analysts were only modeling about US$6.6b in 2029 revenue and US$1.4b in earnings, with a lower 23.7x P/E. Those numbers came before this G7 15 Day Canada launch and guidance lift, so you may want to compare both perspectives yourself.

    Explore 3 other DexCom fair value estimates, including one that suggests it could be worth just $96.46.

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    • A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • See our latest analysis for DexCom. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate DexCom's overall financial health at a glance.

    Looking For More Investment Ideas Beyond DexCom?

    Once you have a view on DexCom, it can help to widen the lens and compare it with other opportunities that match your risk tolerance, income needs, and balance sheet preferences. The Simply Wall St Screener gives you a quick way to surface stocks that fit very different playbooks, so you can build a watchlist that truly suits how you like to invest.